利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

16 条记录 (耗时 0.027 秒)

    METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE
    1.
    发明申请
    METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE 审中-公开
    用于诊断和预防肾损伤和肾功能衰竭的方法和组合

    公开(公告)号：US20160003850A1

    公开(公告)日：2016-01-07

    申请号：US14770442

    申请日：2014-02-26

    申请人： ASTUTE MEDICAL, INC.

    发明人： Joseph ANDERBERG ,  Jeff GRAY ,  Paul MCPHERSON ,  Kevin NAKAMURA ,  James Patrick KAMPF

    IPC分类号： G01N33/68

    CPC分类号： G01N33/6893 ,  G01N2333/4724 ,  G01N2333/565 ,  G01N2333/71 ,  G01N2333/90203 ,  G01N2800/347 ,  G01N2800/60

    摘要： The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Coagulation factor X, Coagulation factor V, soluble Receptor tyrosine-protein kinase erbB-2, Interferon beta, C-type lectin domain family 11 member A, Glyceraldehyde-3-phosphate dehydrogenase, Interferon omega-1, Coagulation factor VIII, Thrombin-Antithrombin-III complex, and soluble Tumor necrosis factor ligand superfamily member 13B as diagnostic and prognostic biomarkers in renal injuries.

    摘要翻译： 本发明涉及用于在患有或疑似患有肾损伤的受试者中监测，诊断，预后和确定治疗方案的方法和组合物。 特别地，本发明涉及使用一种或多种测定法，其被配置为检测选自凝血因子X，凝血因子V，可溶性受体酪氨酸蛋白激酶erbB-2，干扰素β，C型的肾损伤标志物 凝集素结构域家族11成员A，甘油醛-3-磷酸脱氢酶，干扰素ω-1，凝血因子VIII，凝血酶 - 抗凝血酶III复合物和可溶性肿瘤坏死因子配体超家族成员13B作为肾损伤中的诊断和预后生物标志物。

    Markers for Determination of Patient Responsiveness
    4.
    发明申请
    Markers for Determination of Patient Responsiveness 审中-公开
    用于确定患者反应的标记

    公开(公告)号：US20160054320A1

    公开(公告)日：2016-02-25

    申请号：US14781885

    申请日：2014-04-04

    申请人： THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY

    发明人： Ryan D. Schubert ,  Robert C. Axtell ,  Jeffrey Edward Dunn

    IPC分类号： G01N33/569 ,  A61K31/785 ,  A61K38/21 ,  G01N15/14

    CPC分类号： G01N33/56972 ,  A61K31/785 ,  A61K38/215 ,  G01N15/14 ,  G01N33/5052 ,  G01N2015/1006 ,  G01N2015/1486 ,  G01N2333/525 ,  G01N2333/565 ,  G01N2469/10 ,  G01N2800/285 ,  G01N2800/52

    摘要： Compositions and methods are provided for classification of individuals suffering from a demyelinating disease into groups that are informative of the individual's responsiveness or lack of responsiveness to treatment with a J3-interferon (IFNJ3) acting therapy. In particular, it is shown that the effective immunomodulatory treatment of demyelinating disease with IFNJ3 is associated with an increase in circulating transitional B cells in the patient. Diseases of interest include without limitation inflammatory demyelinating diseases of the central nervous system, e.g. multiple sclerosis, neuromyelitis optica (NMO), experimental autoimmune encephalitis (EAE), acute disseminated encephalomyelitis (ADEM), etc.

    摘要翻译： 提供了组合物和方法，用于将患有脱髓鞘疾病的个体分类为对个体的反应性或对J3-干扰素（IFNJ3）作用治疗的治疗缺乏反应性的信息的组。 特别地，显示用IFNJ3对脱髓鞘疾病的有效免疫调节治疗与患者中循环过渡B细胞的增加相关。 感兴趣的疾病包括但不限于中枢神经系统的炎性脱髓鞘疾病，例如， 多发性硬化，神经性脊髓炎（NMO），实验性自身免疫性脑炎（EAE），急性播散性脑脊髓炎（ADEM）等

    Methods For Determining Anti-TNF Therapeutic Response
    6.
    发明申请
    Methods For Determining Anti-TNF Therapeutic Response 审中-公开
    确定抗TNF治疗反应的方法

    公开(公告)号：US20150160236A1

    公开(公告)日：2015-06-11

    申请号：US14557208

    申请日：2014-12-01

    申请人： New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery

    发明人： Mary K. Crow ,  Kleio Mavragani

    IPC分类号： G01N33/68 ,  C12Q1/68

    CPC分类号： G01N33/6866 ,  C12Q1/6876 ,  C12Q1/6883 ,  C12Q1/6897 ,  C12Q2600/106 ,  C12Q2600/158 ,  G01N33/5011 ,  G01N33/564 ,  G01N33/6869 ,  G01N2333/525 ,  G01N2333/545 ,  G01N2333/56 ,  G01N2333/565 ,  G01N2800/52

    摘要： The present invention relates to methods for identifying patients that will respond to treatment with anti-TNF-therapy, i.e., anti-TNF responder patients. In particular, the present invention relates to determining response to an inhibitor of tumor necrosis factor (TNF) in a patient with a chronic inflammatory disease by determining the activity of type I interferon in the patient. The invention further relates to quantification of type I interferon as a measure of predicting responsiveness to anti-TNF therapy in patients with a chronic inflammatory disease such as rheumatoid arthritis (RA), psoriatic arthritis, ankylosing spondylitis, juvenile chronic arthritis, lupus, Crohn's disease, as well as for cardiovascular disease.

    摘要翻译： 本发明涉及用于鉴定将对抗TNF-治疗即抗TNF反应者患者的治疗作出反应的患者的方法。 特别地，本发明涉及通过测定患者中I型干扰素的活性来确定慢性炎性疾病患者中肿瘤坏死因子（TNF）抑制剂的应答。 本发明进一步涉及定量I型干扰素作为预测慢性炎性疾病如类风湿性关节炎（RA），银屑病关节炎，强直性脊柱炎，青少年慢性关节炎，狼疮，克罗恩病的抗TNF治疗的反应性的量度 ，以及心血管疾病。

    Early Diagnosis of Autoimmune and Inflammatory Disorders
    7.
    发明申请
    Early Diagnosis of Autoimmune and Inflammatory Disorders 审中-公开

    公开(公告)号：US20170102392A1

    公开(公告)日：2017-04-13

    申请号：US15175692

    申请日：2016-06-07

    申请人： P3 Innovations LLC

    发明人： Ramesh PAPPU

    IPC分类号： G01N33/68 ,  A61K31/519 ,  G01N33/564 ,  A61K31/47

    CPC分类号： G01N33/6866 ,  A61K31/47 ,  A61K31/519 ,  G01N33/564 ,  G01N2333/56 ,  G01N2333/565 ,  G01N2333/57 ,  G01N2800/50 ,  G01N2800/7095

    摘要： The disclosure relates to methods and assay that assists in the diagnosis of autoimmune and chronic inflammatory disorders such as systemic lupus erythematosus and rheumatoid arthritis by analyzing drug-responsiveness of an interferon signal in a hematological sample (e.g., blood) obtained from a human subject. The assay involves comparing the interferon signal in a control aliquot of the sample with the same interferon sample in an aliquot that has been exposed to a therapeutic modality (e.g., combined with a drug) that is known to be efficacious to treat the disorder. A significant difference between the interferon signals of the control and treated aliquots that corresponds to a characteristic interferon signature for the disorder indicates that the subject is afflicted with, or is likely to develop, the disorder.

    Polymer conjugates of interferon-beta with enhanced biological potency
    8.
    发明授权
    Polymer conjugates of interferon-beta with enhanced biological potency 有权
    具有增强的生物效力的干扰素-β的聚合物缀合物

    公开(公告)号：US09125880B2

    公开(公告)日：2015-09-08

    申请号：US10743068

    申请日：2003-12-23

    申请人： Mark G. P. Saifer ,  Alexa L. Martinez ,  L. David Williams ,  Merry R. Sherman

    发明人： Mark G. P. Saifer ,  Alexa L. Martinez ,  L. David Williams ,  Merry R. Sherman

    IPC分类号： A61K38/21 ,  C07K14/565 ,  A61K38/00 ,  A61K47/48

    CPC分类号： A61K38/215 ,  A61K47/60 ,  C07K14/565 ,  G01N2333/565

    摘要： Methods are provided for the synthesis of polymer conjugates of cytokines and receptor-binding antagonists thereof, especially a non-glycosylated interferon-beta, which conjugates retain unusually high biological potency. Preparation of polymer conjugates according to the methods of the present invention diminishes or avoids steric inhibition of receptor-ligand interactions that commonly results from the attachment of polymers to receptor-binding regions of cytokines, as well as to agonistic and antagonistic analogs thereof. The invention also provides conjugates and compositions produced by such methods. The conjugates of the present invention retain a high level of biological potency compared to those produced by traditional polymer coupling methods that are not targeted to avoid receptor-binding domains of cytokines. In assays in vitro, the biological potency of the conjugates of non-glycosylated interferon-beta of the present invention is substantially higher than that of unconjugated interferon-beta and is similar to that of interferon-beta-1a that is glycosylated. The conjugates of the present invention also exhibit an extended half-life in vivo compared to the corresponding unconjugated cytokine. The present invention also provides kits comprising such conjugates and/or compositions, and methods of use of such conjugates and compositions in a variety of diagnostic, prophylactic and therapeutic applications, including treatment of multiple sclerosis.

    摘要翻译： 提供了用于合成细胞因子和其受体结合拮抗剂的聚合物缀合物的方法，特别是非糖基化的干扰素-β，其结合物保持非常高的生物效力。 根据本发明的方法制备聚合物缀合物减少或避免了通常由聚合物连接到细胞因子的受体结合区域以及其激动剂和拮抗性类似物而引起的受体 - 配体相互作用的空间抑制。 本发明还提供了通过这些方法制备的缀合物和组合物。 与不是为了避免细胞因子的受体结合结构域靶向的传统聚合物偶联方法制备的那些相比，本发明的缀合物保持高水平的生物效力。 在体外测定中，本发明的非糖基化干扰素-β缀合物的生物学效力明显高于未缀合的干扰素-β的生物效力，并且与经糖基化的干扰素-β-1a相似。 与相应的未结合的细胞因子相比，本发明的缀合物在体内也表现出延长的半衰期。 本发明还提供包含这种缀合物和/或组合物的试剂盒，以及在多种诊断，预防和治疗应用中使用这种缀合物和组合物的方法，包括治疗多发性硬化。